Cargando…

Candesartan Cilexetil Improves Angiotensin II Type 2 Receptor–Mediated Neurite Outgrowth via the PI3K-Akt Pathway in Fructose-Induced Insulin-Resistant Rats

We have shown previously that stimulation of the angiotensin II type 2 receptor (AT(2)R) results in nerve facilitation. In this study, we determined the capacity of candesartan to correct expression patterns characteristic of neuropathy and AT(2)R-mediated neurite outgrowth in the fructose-induced i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashikawa-Hobara, Narumi, Hashikawa, Naoya, Inoue, Yusuke, Sanda, Hitomi, Zamami, Yoshito, Takatori, Shingo, Kawasaki, Hiromu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Complications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314356/ https://www.ncbi.nlm.nih.gov/pubmed/22357959 http://dx.doi.org/10.2337/db11-1468

Ejemplares similares

Calcitonin gene-related peptide pre-administration acts as a novel antidepressant in stressed mice
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2015)

HSP105 prevents depression-like behavior by increasing hippocampal brain-derived neurotrophic factor levels in mice
por: Hashikawa, Naoya, et al.
Publicado: (2017)

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Effects from the induction of heat shock proteins in a murine model due to progression of aortic atherosclerosis
por: Hashikawa, Naoya, et al.
Publicado: (2021)

Intranasal calcitonin gene-related peptide administration impairs fear memory retention in mice through the PKD/p-HDAC5/Npas4 pathway
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2022)

CGRP overexpression does not alter depression-like behavior in mice
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2021)

Lactobacillus paragasseri OLL2809 Improves Depression-Like Behavior and Increases Beneficial Gut Microbes in Mice
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2022)

Candesartan cilexetil: COVID-19 pneumonia: case report
Publicado: (2020)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
por: Xu, Lanlan, et al.
Publicado: (2021)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Npas4 impairs fear memory via phosphorylated HDAC5 induced by CGRP administration in mice
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2021)

Design and development and evaluation of candesartan cilexetil liquid filling formulations
por: Deepthi, Y., et al.
Publicado: (2015)

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
por: Sravya, Maddukuri, et al.
Publicado: (2013)

Candesartan Attenuates Diabetic Retinal Vascular Pathology by Restoring Glyoxalase-I Function
por: Miller, Antonia G., et al.
Publicado: (2010)

The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media
por: Hoppe, Katarzyna, et al.
Publicado: (2014)

Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug
por: Aly, Usama Farghaly, et al.
Publicado: (2020)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
por: Mady, Omar Y., et al.
Publicado: (2021)

Chemometric Methods for Simultaneous Determination of Candesartan Cilexetil and Hydrochlorothiazide in Binary Combinations
por: Ali, Diyar Salahuddin
Publicado: (2023)

Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study
por: Detroja, Chetan, et al.
Publicado: (2011)

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study
por: Baguet, JP, et al.
Publicado: (2009)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
por: Figueroa-Campos, Andrés, et al.
Publicado: (2020)

Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion
por: Kamalakkannan, V, et al.
Publicado: (2013)

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
por: Mengden, Thomas, et al.
Publicado: (2009)

Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions
por: Tjandrawinata, Raymond R, et al.
Publicado: (2013)

Nephroprotective effects of Candesartan Cilexetil against Cyclosporine A-induced nephrotoxicity in a rat model
por: Ghafil, Fadhaa Abdulameer, et al.
Publicado: (2022)

The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia
por: Quinlan, Sean, et al.
Publicado: (2019)

New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets
por: Belal, Tarek S., et al.
Publicado: (2013)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
por: AbuElfadl, Aya, et al.
Publicado: (2021)

Early-Outgrowth Bone Marrow Cells Attenuate Renal Injury and Dysfunction via an Antioxidant Effect in a Mouse Model of Type 2 Diabetes
por: Zhang, Yanling, et al.
Publicado: (2012)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
por: Poudel, Surendra, et al.
Publicado: (2021)

Reversal of Bone Marrow Mobilopathy and Enhanced Vascular Repair by Angiotensin-(1-7) in Diabetes
por: Vasam, Goutham, et al.
Publicado: (2017)

Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials
por: Féghali, Ramzi EL, et al.
Publicado: (2007)

A validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product
por: Kumar, Namala Durga Atchuta, et al.
Publicado: (2012)

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration
por: Anwar, Walid, et al.
Publicado: (2020)

Angiotensin II Type 1 Receptor Signaling Contributes to Synaptophysin Degradation and Neuronal Dysfunction in the Diabetic Retina
por: Kurihara, Toshihide, et al.
Publicado: (2008)

Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model
por: YAN, WEN-HUA, et al.
Publicado: (2016)

Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction
por: Chang, Gwo‐Jyh, et al.
Publicado: (2022)

Pharmacokinetics and bioequivalence of fixed-dose combination of candesartan cilexetil/amlodipine besylate (16/10 mg) versus coadministration of individual formulations in healthy subjects
por: Lee, Hae Won, et al.
Publicado: (2020)

Cholecystokinin Plays a Novel Protective Role in Diabetic Kidney Through Anti-inflammatory Actions on Macrophage: Anti-inflammatory Effect of Cholecystokinin
por: Miyamoto, Satoshi, et al.
Publicado: (2012)

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study
por: Rakugi, Hiromi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bl6d2qcris0p6qtul62qm32jbv